{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:41:14Z","timestamp":1785544874432,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,29]]},"DOI":"10.7759\/cureus.68117","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:13:22Z","timestamp":1724944402000},"source":"Crossref","is-referenced-by-count":8,"title":["New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Amir","family":"Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadab","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Zeeshan","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salamat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binay K","family":"Panjiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert M","year":"2010","unstructured":"Humbert M, Sitbon O, Ya\u00efci A, et al.. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010, 36:549-55. 10.1183\/09031936.00057010","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension","volume":"21","author":"Bisserier M","year":"2020","unstructured":"Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med. 2020, 21:163-79. 10.31083\/j.rcm.2020.02.597","journal-title":"Rev Cardiovasc Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8 N","year":"2013","unstructured":"Gali\u00e8 N, Corris PA, Frost A, et al.. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013, 62:D60-72. 10.1016\/j.jacc.2013.10.031","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani HA","year":"2013","unstructured":"Ghofrani HA, Gali\u00e8 N, Grimminger F, et al.. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013, 369:330-40. 10.1056\/NEJMoa1209655","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th World Symposium on Pulmonary Hypertension","volume":"53","author":"Gali\u00e8 N","year":"2019","unstructured":"Gali\u00e8 N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019, 53:10.1183\/13993003.02148-2018","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau G","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, et al.. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013, 62:D34-41. 10.1016\/j.jacc.2013.10.029","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome","volume":"115","author":"Lai YC","year":"2014","unstructured":"Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014, 115:115-30. 10.1161\/CIRCRESAHA.115.301146","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-0998-0","article-title":"Vascular remodeling in pulmonary hypertension","volume":"91","author":"Shimoda LA","year":"2013","unstructured":"Shimoda LA, Laurie SS. Vascular remodeling in pulmonary hypertension. J Mol Med (Berl). 2013, 91:297-309. 10.1007\/s00109-013-0998-0","journal-title":"J Mol Med (Berl)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01904-2018","article-title":"Diagnosis of pulmonary hypertension","volume":"53","author":"Frost A","year":"2019","unstructured":"Frost A, Badesch D, Gibbs JS, et al.. Diagnosis of pulmonary hypertension. Eur Respir J. 2019, 53:10.1183\/13993003.01904-2018","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121792","article-title":"Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial hypertension","volume":"621","author":"Dhoble S","year":"2022","unstructured":"Dhoble S, Patravale V, Weaver E, Lamprou DA, Patravale T. Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial hypertension. Int J Pharm. 2022, 621:121792. 10.1016\/j.ijpharm.2022.121792","journal-title":"Int J Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.05.006","article-title":"Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIB clinical trial","volume":"41","author":"Chang HJ","year":"2019","unstructured":"Chang HJ, Song S, Chang SA, et al.. Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIB clinical trial. Clin Ther. 2019, 41:1499-507. 10.1016\/j.clinthera.2019.05.006","journal-title":"Clin Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost AE","year":"2015","unstructured":"Frost AE, Barst RJ, Hoeper MM, et al.. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015, 34:1366-75. 10.1016\/j.healun.2015.05.025","journal-title":"J Heart Lung Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14621","article-title":"Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial","volume":"176","author":"Hobbs AJ","year":"2019","unstructured":"Hobbs AJ, Moyes AJ, Baliga RS, et al.. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Br J Pharmacol. 2019, 176:1251-67. 10.1111\/bph.14621","journal-title":"Br J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert M","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JS, et al.. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021, 384:1204-15. 10.1056\/NEJMoa2024277","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1024OC","article-title":"Anastrozole in pulmonary arterial hypertension. A randomized, double-blind, placebo-controlled trial","volume":"195","author":"Kawut SM","year":"2017","unstructured":"Kawut SM, Archer-Chicko CL, DeMichele A, et al.. Anastrozole in pulmonary arterial hypertension. A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2017, 195:360-8. 10.1164\/rccm.201605-1024OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin LJ","year":"2015","unstructured":"Rubin LJ, Gali\u00e8 N, Grimminger F, et al.. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015, 45:1303-13. 10.1183\/09031936.00090614","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter E","year":"2017","unstructured":"Spiekerkoetter E, Sung YK, Sudheendra D, et al.. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J. 2017, 50:10.1183\/13993003.02449-2016","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres F","year":"2019","unstructured":"Torres F, Farber H, Ristic A, et al.. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019, 54:10.1183\/13993003.01030-2019","journal-title":"Eur Respir J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland M","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008, 31:891-901. 10.1183\/09031936.00097107","journal-title":"Eur Respir J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6215","article-title":"Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy","volume":"2","author":"Buckley MS","year":"2010","unstructured":"Buckley MS, Staib RL, Wicks LM, Feldman JP. Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Drug Healthc Patient Saf. 2010, 2:151-61. 10.2147\/DHPS.S6215","journal-title":"Drug Healthc Patient Saf"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta\u2010analysis of 4894 patients from 24 randomized double\u2010blind placebo\u2010controlled clinical trials","volume":"5","author":"Wei A","year":"2016","unstructured":"Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, Pu J. Clinical adverse effects of endothelin receptor antagonists: insights from the meta\u2010analysis of 4894 patients from 24 randomized double\u2010blind placebo\u2010controlled clinical trials. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.116.003896","journal-title":"J Am Heart Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study","volume":"47","author":"Kreisel W","year":"2015","unstructured":"Kreisel W, Deibert P, Kupcinskas L, et al.. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015, 47:144-50. 10.1016\/j.dld.2014.10.018","journal-title":"Dig Liver Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10295","article-title":"Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study","volume":"138","author":"Benza RL","year":"2010","unstructured":"Benza RL, Gupta H, Soto FJ, Park MH, Torres F, Frey N, Murali S. Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study. Chest. 2010, 138:840. 10.1378\/chest.10295","journal-title":"Chest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed WS","year":"2021","unstructured":"Ahmed WS, Geethakumari AM, Biswas KH. Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother. 2021, 134:111128. 10.1016\/j.biopha.2020.111128","journal-title":"Biomed Pharmacother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani HA","year":"2010","unstructured":"Ghofrani HA, Morrell NW, Hoeper MM, et al.. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010, 182:1171-7. 10.1164\/rccm.201001-0123OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper MM","year":"2013","unstructured":"Hoeper MM, Barst RJ, Bourge RC, et al.. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013, 127:1128-38. 10.1161\/CIRCULATIONAHA.112.000765","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung LM","year":"2020","unstructured":"Yung LM, Yang P, Joshi S, et al.. ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020, 12:10.1126\/scitranslmed.aaz5660","journal-title":"Sci Transl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov KM","year":"2014","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al.. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014, 165:814-23. 10.1111\/bjh.12835","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini MD","year":"2019","unstructured":"Cappellini MD, Porter J, Origa R, et al.. Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019, 104:477-84. 10.3324\/haematol.2018.198887","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.08.001","article-title":"Sotatercept safety and effects on hemoglobin, bone, and vascular calcification","volume":"4","author":"Coyne DW","year":"2019","unstructured":"Coyne DW, Singh HN, Smith WT, et al.. Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. Kidney Int Rep. 2019, 4:1585-97. 10.1016\/j.ekir.2019.08.001","journal-title":"Kidney Int Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji R","year":"2018","unstructured":"Komrokji R, Garcia-Manero G, Ades L, et al.. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018, 5:63-72. 10.1016\/S2352-3026(18)30002-4","journal-title":"Lancet Haematol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2929-9","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos H","year":"2016","unstructured":"Raftopoulos H, Laadem A, Hesketh PJ, et al.. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016, 24:1517-25. 10.1007\/s00520-015-2929-9","journal-title":"Support Care Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman ML","year":"2013","unstructured":"Sherman ML, Borgstein NG, Mook L, et al.. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013, 53:1121-30. 10.1002\/jcph.160","journal-title":"J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0483OC","article-title":"Sex-dependent influence of endogenous estrogen in pulmonary hypertension","volume":"190","author":"Mair KM","year":"2014","unstructured":"Mair KM, Wright AF, Duggan N, et al.. Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med. 2014, 190:456-67. 10.1164\/rccm.201403-0483OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvv106","article-title":"Oestrogen receptor alpha in pulmonary hypertension","volume":"106","author":"Wright AF","year":"2015","unstructured":"Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, Maclean MR. Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc Res. 2015, 106:206-16. 10.1093\/cvr\/cvv106","journal-title":"Cardiovasc Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp LH","year":"2015","unstructured":"Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015, 120:56-71. 10.1016\/j.prostaglandins.2015.04.007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter E","year":"2013","unstructured":"Spiekerkoetter E, Tian X, Cai J, et al.. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013, 123:3600-13. 10.1172\/JCI65592","journal-title":"J Clin Invest"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension","volume":"192","author":"Spiekerkoetter E","year":"2015","unstructured":"Spiekerkoetter E, Sung YK, Sudheendra D, et al.. Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015, 192:254-7. 10.1164\/rccm.201411-2061LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger F","year":"2009","unstructured":"Grimminger F, Weimann G, Frey R, et al.. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009, 33:785-92. 10.1183\/09031936.00039808","journal-title":"Eur Respir J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(88)80375-2","article-title":"Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide","volume":"232","author":"Kenny AJ","year":"1988","unstructured":"Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 1988, 232:1-8. 10.1016\/0014-5793(88)80375-2","journal-title":"FEBS Lett"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.3.2.2521610","article-title":"Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones","volume":"3","author":"Erd\u00f6s EG","year":"1989","unstructured":"Erd\u00f6s EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989, 3:145-51.","journal-title":"FASEB J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(99)00152-1","article-title":"An overview of clinical studies with racecadotril in adults","volume":"14","author":"Lecomte J","year":"2000","unstructured":"Lecomte J. An overview of clinical studies with racecadotril in adults. Int J Antimicrob Agents. 2000, 14:81-7. 10.1016\/S0924-8579(99)00152-1","journal-title":"Int J Antimicrob Agents"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236294-new-and-emerging-therapeutic-drugs-for-the-treatment-of-pulmonary-arterial-hypertension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:13:25Z","timestamp":1724944405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236294-new-and-emerging-therapeutic-drugs-for-the-treatment-of-pulmonary-arterial-hypertension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.68117","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}